Sal Giovine

Mr. Giovine is a highly experienced finance leader who has spent approximately 20 years in diverse healthcare and biopharma settings. He has led successful finance teams across strategy and execution, business and corporate development, R&D, and commercialization. He joined Xilio from Johnson & Johnson (NYSE: JNJ), where he spent 15 years, most recently with Janssen Biotech, Inc. leading finance for the $5 billion NTS U.S. Oncology business. Over the course of three years, Mr. Giovine led all commercial finance aspects of DARZALEX®, IMBRUVICA®, ERLEADA®, ZYTIGA®, and BALVERSA®, which collectively grew by more than 30% and more than $1 billion annually. Preceding this role, Mr. Giovine spent four years leading finance for Johnson & Johnson’s Corporate Venture Capital Group. In this capacity, he led financial aspects of over 200 equity capital investments in over 75 companies leading to various licensing and M&A transactions. Prior to Johnson & Johnson, he was an associate at Deloitte LLP. Mr. Giovine holds a B.S. in Accounting and an MBA in Corporate Finance, both from Fordham University in New York.